par Lenclud, Christine;Chapelle, Pierre;Van Muylem, Alain 
;Linkowski, Paul ;Yernault, Jean Claude
Référence Current therapeutic research, 59, 4, page (234-243)
Publication Publié, 1998
;Linkowski, Paul ;Yernault, Jean Claude Référence Current therapeutic research, 59, 4, page (234-243)
Publication Publié, 1998
Article révisé par les pairs
| Résumé : | The efficacy of bedtime nasal instillation of chondroitin sulfate solution was tested in a double-masked, crossover, placebo-controlled trial of seven nonapneic subjects who snored. Subjects were assessed for reduction in snoring using conventional polysomnographic studies. The analysis of snoring was performed using the recordings obtained by a multidirectional microphone placed above the subject's head. Snoring was defined as an inspiratory, raspy, snort-like sound. The percentage of total sleep time (TST) spent snoring and the equal energy level related to sleep were calculated for each nocturnal sleep recording. Results of the sleep studies were similar with placebo and chondroitin sulfate. However, the mean percentage of TST spent snoring decreased from 46.5% with placebo to 31.3% with chondroitin sulfate, with important interindividual differences. Differences in the equivalent noise level related to TST decrease in the five subjects who were adequately recorded (74.1 ± 5.6 dB vs 70.0 ± 4.9 dB) did not reach statistical significance. Results of this study suggest that chondroitin sulfate, a long-acting tissue-coating agent, has the potential to reduce snoring. |
